MARKET

ATNX

ATNX

Athenex
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.70
-0.19
-1.37%
Closed 16:07 11/25 EST
OPEN
13.84
PREV CLOSE
13.89
HIGH
14.07
LOW
13.59
VOLUME
386.58K
TURNOVER
--
52 WEEK HIGH
18.35
52 WEEK LOW
5.63
MARKET CAP
1.28B
P/E (TTM)
-9.4450
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Athenex To Present Data On Oral Paclitaxel And Encequidar At 2020 San Antonio Breast Cancer Symposium Dec. 9
Spotlight poster on updated PFS and OS data from the pivotal Phase 3 clinical trial of oral paclitaxel in metastatic breast cancer BUFFALO, N.Y., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a
Benzinga · 11/17 13:09
Athenex Announces Data on Oral Paclitaxel and Encequidar to be Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)
* Spotlight poster on updated PFS and OS data from the pivotal Phase 3 clinical trial of oral paclitaxel in metastatic breast cancer BUFFALO, N.Y., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that oral paclitaxel and encequidar (“oral paclitaxel”) data will be presented in four separate poster presentations at the 2020 San Antonio Breast Cancer Symposium (SABCS) to be held virtually December 8-11. Presentations will include, from the pivotal Phase 3 clinical trial of oral paclitaxel in metastatic breast cancer (MBC), a spotlight poster on progression-free survival (PFS) and overall survival (OS), and posters on neuropathy (CIPN), and management of gastrointestinal (GI) side effects. An additional poster explores oral paclitaxel in the treatment of cutaneous angiosarcoma of the breast.The symposium will also feature an immersive Athenex Oncology virtual exhibit experience with distinct hubs for CIPN, Medical Affairs, and the Facing MBC Together program.Details of the oral paclitaxel presentations are as follows: Spotlight Poster PresentationAbstract Title: Oral Paclitaxel and Encequidar (oPac+E) versus IV Paclitaxel (IVPac) in the treatment of metastatic breast cancer (mBC) patients (Study: KX-ORAX-001)Session: Spotlight Poster Discussion 1Program Number: PD1-08Date and Time: Wednesday, December 9, 2020, at 4:00 PM to 5:15 PM Central Time (CT)For more information, please visit: https://www.sabcs.org/Program/Spotlight-Sessions/Spotlight-Poster-Discussion-1Abstracts selected for spotlight poster presentation will only have titles posted to the SABCS website until the embargo lifts on December 9, 2020, when the complete abstract will post online. Additional Poster PresentationsAbstract Title: A phase 2 study of Oral Paclitaxel and Encequidar (oPac+E) in the treatment of cutaneous angiosarcoma: the breast angiosarcoma groupProgram Number: PS13-05Session: Poster Session 13Date and Time: Wednesday, December 9, 2020, at 8:00 AM CTFor more information, please visit: https://www.sabcs.org/Program/Poster-Sessions/Poster-Session-13 Abstract Title: Lower rates of neuropathy with Oral Paclitaxel and Encequidar (oPac+E) compared to IV Paclitaxel (IVPac) in treatment of metastatic breast cancer (mBC): Study KX-ORAX-001Program Number: PS13-06Session: Poster Session 13Date and Time: Wednesday, December 9, 2020, at 8:00 AM CTFor more information, please visit: https://www.sabcs.org/Program/Poster-Sessions/Poster-Session-13 Abstract Title: Oral Paclitaxel and Encequidar (oPac+E) in the treatment of metastatic breast cancer (mBC): Management of gastrointestinal adverse events (GI AE). Study KX-ORAX-001Program Number: PS13-11Session: Poster Session 13Date and Time: Wednesday, December 9, 2020, at 8:00 AM CTFor more information, please visit: https://www.sabcs.org/Program/Poster-Sessions/Poster-Session-13 Athenex Exhibit BoothAthenex Oncology will have an immersive virtual exhibit experience at SABCS. This unique booth will feature three separate hubs: 1) Chemotherapy-Induced Peripheral Neuropathy (CIPN) augmented reality simulation, designed to deepen a visitor’s understanding and virtually experience what it feels like to have CIPN; 2) Facing MBC Together, a public education and patient support program that addresses the issue of isolation for people living with metastatic breast cancer; and 3) Medical Affairs, where visitors can learn about how inhibition of P-gp facilitates absorption of orally administered chemotherapies. The booth will be accessible to meeting registrants throughout SABCS during exhibit hall hours, which are from 10am-7pm on Tuesday, December 8; 8am-7:45pm on Wednesday, December 9; and 10am-5pm on Thursday and Friday, December 10 and 11 (all Central Time). About Athenex, Inc. Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform, and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation therapy. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan; multiple locations in Chongqing, China; Manchester, UK; Guatemala City, Guatemala and Buenos Aires, Argentina. For more information, please visit www.athenex.com.About Oral Paclitaxel Athenex’s oral paclitaxel and encequidar (“oral paclitaxel”) is the first oral formulation of paclitaxel in late-stage development for the treatment of metastatic breast cancer (MBC), and is also in earlier stages of development for other malignancies. Data from a pivotal phase 3, open-label, randomized, multicenter study involving more than 400 patients with MBC suggests that oral paclitaxel is superior to IV paclitaxel in terms of efficacy (as measured by confirmed tumor response) and tolerability. Encequidar, the cornerstone of Athenex’s Orascovery technology platform, is a highly specific and potent inhibitor of an active transport protein called P-glycoprotein (P-gp) in the gastrointestinal (GI) tract. By localizing P-gp inhibitory activity in the GI tract, encequidar improves the absorption of chemotherapeutic agents while limiting the potential for unnecessary P-gp inhibition at other sites in the body. The potency, selectivity, and non-systemic absorption of encequidar enables the administration of many traditional IV chemotherapies more easily, allowing for greater bioavailability and a potentially longer duration of therapy. On September 1, 2020, Athenex announced that the FDA accepted the Company’s New Drug Application (NDA) for Oral Paclitaxel for the treatment of MBC and granted the application Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2021.Forward-Looking Statements Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. These forward-looking statements are typically identified by terms such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the development stage of our primary clinical candidates and related risks involved in drug development, clinical trials, regulation, manufacturing and commercialization; our reliance on third parties for success in certain areas of Athenex’s business; our history of operating losses and need to raise additional capital to continue as a going concern; uncertainties around our ability to meet funding conditions under our financing agreements and access to capital thereunder; risks and uncertainties related to the COVID-19 pandemic and its potential impact on our operations, cash flow and financial condition; competition; intellectual property risks; risks relating to doing business internationally and in China; the risk of production slowdowns or stoppages or other interruptions at our Chongqing facilities; and the other risk factors set forth from time to time in our SEC filings, copies of which are available for free in the Investor Relations section of our website at http://ir.athenex.com/phoenix.zhtml?c=254495&p=irol-sec or upon request from our Investor Relations Department. All information provided in this release is as of the date hereof and we assume no obligation and do not intend to update these forward-looking statements, except as required by law.CONTACTSInvestors Steve Rubis Athenex, Inc. Email: stevenrubis@athenex.comDaniel Lang, MD Athenex, Inc. Email: danlang@athenex.comMedia Gloria Gasaatura LifeSci Advisors, LLC Email: ggasaatura@lifesciadvisors.com
GlobeNewswire · 11/17 13:05
Athenex, Inc. 2020 Q3 - Results - Earnings Call Presentation
The following slide deck was published by Athenex, Inc. in conjunction with their 2020 Q3 earnings call.
Seekingalpha · 11/08 19:39
Athenex Q3 EPS $(0.44) Misses $(0.43) Estimate, Sales $35.48M Beat $23.11M Estimate
Athenex (NASDAQ:ATNX) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 2.22 percent increase over losses of $(0.45) per share from the same
Benzinga · 11/05 12:16
Athenex EPS in-line, beats on revenue
Athenex (ATNX): Q3 Non-GAAP EPS of -$0.40 in-line; GAAP EPS of -$0.44 beats by $0.03.Revenue of $35.48M (+83.3% Y/Y) beats by $12.37M.Shares -0.08% PM.Press Release
Seekingalpha · 11/05 12:12
Athenex, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 5, 2020 / Athenex, Inc.
ACCESSWIRE · 11/05 11:15
Benzinga's Top Upgrades, Downgrades For October 26, 2020
Upgrades * Wedbush upgraded the previous rating for Huntington Bancshares Inc (NASDAQ: HBAN) from Neutral to Outperform. Huntington Bancshares earned $0.27 in the third quarter, compared to $0.34 in the year-ago quarter. The current stock performance of Huntington Bancshares shows a 52-week-high of 15.63 and a 52-week-low of 6.82. Moreover, at the end of the last trading period, the closing price was at $10.47. * For Toll Brothers Inc (NYSE: TOL), Raymond James upgraded the previous rating of Market Perform to the current rating Outperform. For the third quarter, Toll Brothers had an EPS of $0.90, compared to year-ago quarter EPS of $1.00. The current stock performance of Toll Brothers shows a 52-week-high of 50.415 and a 52-week-low of 13.28. Moreover, at the end of the last trading period, the closing price was at $47.28. * For PulteGroup Inc (NYSE: PHM), Raymond James upgraded the previous rating of Outperform to the current rating Strong Buy. For the third quarter, PulteGroup had an EPS of $1.34, compared to year-ago quarter EPS of $1.01. The current stock performance of PulteGroup shows a 52-week-high of 49.7 and a 52-week-low of 17.12. Moreover, at the end of the last trading period, the closing price was at $44.02. * Raymond James upgraded the previous rating for D.R. Horton Inc (NYSE: DHI) from Market Perform to Outperform. For the third quarter, D.R. Horton had an EPS of $1.72, compared to year-ago quarter EPS of $1.26. The stock has a 52-week-high of 81.21 and a 52-week-low of 25.51. At the end of the last trading period, D.R. Horton closed at $73.07. * Raymond James upgraded the previous rating for Live Oak Bancshares Inc (NASDAQ: LOB) from Outperform to Strong Buy. For the third quarter, Live Oak Bancshares had an EPS of $0.81, compared to year-ago quarter EPS of $0.10. At the moment, the stock has a 52-week-high of 34.79 and a 52-week-low of 7.57. Live Oak Bancshares closed at $33.71 at the end of the last trading period. * Raymond James upgraded the previous rating for First Midwest Bancorp Inc (NASDAQ: FMBI) from Market Perform to Outperform. In the third quarter, First Midwest Bancorp showed an EPS of $0.33, compared to $0.52 from the year-ago quarter. The current stock performance of First Midwest Bancorp shows a 52-week-high of 23.64 and a 52-week-low of 10.31. Moreover, at the end of the last trading period, the closing price was at $12.61. * For Crown Castle International Corp (NYSE: CCI), Raymond James upgraded the previous rating of Market Perform to the current rating Outperform. For the third quarter, Crown Castle Intl had an EPS of $1.56, compared to year-ago quarter EPS of $1.55. At the moment, the stock has a 52-week-high of 180.0 and a 52-week-low of 114.18. Crown Castle Intl closed at $158.59 at the end of the last trading period. * Societe Generale upgraded the previous rating for TechnipFMC PLC (NYSE: FTI) from Hold to Buy. TechnipFMC earned $0.16 in the third quarter, compared to $0.12 in the year-ago quarter. The current stock performance of TechnipFMC shows a 52-week-high of 23.62 and a 52-week-low of 4.49. Moreover, at the end of the last trading period, the closing price was at $6.48. * According to Roth Capital, the prior rating for First Solar Inc (NASDAQ: FSLR) was changed from Neutral to Buy. First Solar earned $0.39 in the second quarter, compared to $0.18 in the year-ago quarter. The current stock performance of First Solar shows a 52-week-high of 87.44 and a 52-week-low of 28.47. Moreover, at the end of the last trading period, the closing price was at $85.37. * Goldman Sachs upgraded the previous rating for Check Point Software Technologies Ltd (NASDAQ: CHKP) from Sell to Neutral. For the third quarter, Check Point Software had an EPS of $1.64, compared to year-ago quarter EPS of $1.44. The stock has a 52-week-high of 130.98 and a 52-week-low of 80.06. At the end of the last trading period, Check Point Software closed at $120.47. * For Amgen Inc (NASDAQ: AMGN), Raymond James upgraded the previous rating of Market Perform to the current rating Outperform. In the second quarter, Amgen showed an EPS of $4.25, compared to $3.97 from the year-ago quarter. At the moment, the stock has a 52-week-high of 264.97 and a 52-week-low of 177.05. Amgen closed at $227.16 at the end of the last trading period. * For Installed Building Products Inc (NYSE: IBP), KeyBanc upgraded the previous rating of Sector Weight to the current rating Overweight. For the second quarter, Installed Building Prods had an EPS of $1.12, compared to year-ago quarter EPS of $0.87. The stock has a 52-week-high of 121.67 and a 52-week-low of 29.0201. At the end of the last trading period, Installed Building Prods closed at $106.50. Downgrades * Wedbush downgraded the previous rating for KeyCorp (NYSE: KEY) from Outperform to Neutral. In the third quarter, KeyCorp showed an EPS of $0.41, compared to $0.48 from the year-ago quarter. The stock has a 52-week-high of 20.525 and a 52-week-low of 7.45. At the end of the last trading period, KeyCorp closed at $13.46. * For SunPower Corp (NASDAQ: SPWR), Credit Suisse downgraded the previous rating of Outperform to the current rating Neutral. In the second quarter, SunPower showed an EPS of $0.22, compared to $0.22 from the year-ago quarter. At the moment, the stock has a 52-week-high of 19.38 and a 52-week-low of 4.03. SunPower closed at $16.86 at the end of the last trading period. * Credit Suisse downgraded the previous rating for First Solar Inc (NASDAQ: FSLR) from Neutral to Underperform. For the second quarter, First Solar had an EPS of $0.39, compared to year-ago quarter EPS of $0.18. The current stock performance of First Solar shows a 52-week-high of 87.44 and a 52-week-low of 28.47. Moreover, at the end of the last trading period, the closing price was at $85.37. Initiations * Morgan Stanley initiated coverage on Palantir Technologies Inc (NYSE: PLTR) with an Overweight rating. The price target for Palantir Technologies is set to $13.00. The stock has a 52-week-high of 11.42 and a 52-week-low of 8.9. At the end of the last trading period, Palantir Technologies closed at $9.48. * Morgan Stanley initiated coverage on Asana Inc (NYSE: ASAN) with a Equal-Weight rating. The price target for Asana is set to $27.00. The stock has a 52-week-high of 29.96 and a 52-week-low of 22.9. At the end of the last trading period, Asana closed at $23.51. * For FibroGen Inc (NASDAQ: FGEN), Raymond James initiated coverage, by setting the current rating at Underperform. FibroGen earned $0.95 in the second quarter, compared to $1.26 in the year-ago quarter. At the moment, the stock has a 52-week-high of 51.56 and a 52-week-low of 22.65. FibroGen closed at $42.60 at the end of the last trading period. * SVB Leerink initiated coverage on Athenex Inc (NASDAQ: ATNX) with an Outperform rating. The price target for Athenex is set to $22.00. Athenex earned $0.41 in the second quarter, compared to $0.44 in the year-ago quarter. The current stock performance of Athenex shows a 52-week-high of 18.35 and a 52-week-low of 5.63. Moreover, at the end of the last trading period, the closing price was at $11.45. * JP Morgan initiated coverage on Zscaler Inc (NASDAQ: ZS) with an Overweight rating. The price target for Zscaler is set to $190.00. For the fourth quarter, Zscaler had an EPS of $0.05, compared to year-ago quarter EPS of $0.07. The current stock performance of Zscaler shows a 52-week-high of 163.8 and a 52-week-low of 35.0. Moreover, at the end of the last trading period, the closing price was at $147.05. * Morgan Stanley initiated coverage on Yalla Group Ltd (NYSE: YALA) with a Equal-Weight rating. The stock has a 52-week-high of 10.99 and a 52-week-low of 6.26. At the end of the last trading period, Yalla Group closed at $8.93. * JP Morgan initiated coverage on Sapiens International Corp NV (NASDAQ: SPNS) with an Overweight rating. The price target for Sapiens Intl Corp is set to $40.00. Sapiens Intl Corp earned $0.26 in the second quarter, compared to $0.19 in the year-ago quarter. The current stock performance of Sapiens Intl Corp shows a 52-week-high of 35.23 and a 52-week-low of 13.55. Moreover, at the end of the last trading period, the closing price was at $28.99. * RBC Capital initiated coverage on Palantir Technologies Inc (NYSE: PLTR) with a Sector Perform rating. The price target for Palantir Technologies is set to $11.00. The current stock performance of Palantir Technologies shows a 52-week-high of 11.42 and a 52-week-low of 8.9. Moreover, at the end of the last trading period, the closing price was at $9.48. * With a current rating of Equal-Weight, Wells Fargo initiated coverage on Pulmonx Corp (NASDAQ: LUNG). The price target seems to have been set at $46.00 for Pulmonx. At the moment, the stock has a 52-week-high of 52.0 and a 52-week-low of 37.64. Pulmonx closed at $42.24 at the end of the last trading period. * JMP Securities initiated coverage on HOOKIPA Pharma Inc (NASDAQ: HOOK) with a Market Outperform rating. The price target for HOOKIPA Pharma is set to $19.00. For the second quarter, HOOKIPA Pharma had an EPS of $0.28, compared to year-ago quarter EPS of $0.63. At the moment, the stock has a 52-week-high of 14.3662 and a 52-week-low of 5.8. HOOKIPA Pharma closed at $9.60 at the end of the last trading period. * With a current rating of Buy, Stifel initiated coverage on CuriosityStream Inc (NASDAQ: CURI). The price target seems to have been set at $12.00 for CuriosityStream. At the moment, the stock has a 52-week-high of 11.64 and a 52-week-low of 8.9. CuriosityStream closed at $9.05 at the end of the last trading period. * JP Morgan initiated coverage on Mission Produce Inc (NASDAQ: AVO) with an Overweight rating. The price target for Mission Produce is set to $18.00. At the moment, the stock has a 52-week-high of 15.03 and a 52-week-low of 11.75. Mission Produce closed at $13.17 at the end of the last trading period. * Jefferies initiated coverage on Asana Inc (NYSE: ASAN) with a Buy rating. The price target for Asana is set to $30.00. The current stock performance of Asana shows a 52-week-high of 29.96 and a 52-week-low of 22.9. Moreover, at the end of the last trading period, the closing price was at $23.51. * With a current rating of Market Perform, Keefe, Bruyette & Woods initiated coverage on AppFolio Inc (NASDAQ: APPF). The price target seems to have been set at $150.00 for AppFolio. In the second quarter, AppFolio showed an EPS of $0.54, compared to $0.05 from the year-ago quarter. The stock has a 52-week-high of 180.5595 and a 52-week-low of 81.01. At the end of the last trading period, AppFolio closed at $153.00.See more from Benzinga * Click here for options trades from Benzinga * Unusual Options Activity Insight: America Movil * Understanding Oracle's Unusual Options Activity(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 10/26 14:08
Athenex, Inc. to Report Third Quarter 2020 Earnings Results on November 5, 2020
BUFFALO, N.Y., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will release third quarter 2020 financial results on Thursday, November 5, 2020, before the market opens, and host a conference call and live audio webcast 8:00am Eastern Time to discuss financial results and provide a business update. To participate in the call, dial 877-407-0784 (domestic) or 201-689-8560 (international) fifteen minutes before the conference call begins and reference the conference passcode 13711719. The live conference call and replay can also be accessed via audio webcast at the Investor Relations section of the Company’s website, located at http://ir.athenex.com/.About Athenex, Inc. Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation therapy. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active treatments with improved tolerability profiles. Athenex has offices in the United States, Hong Kong, China, Taiwan, the United Kingdom and Latin America. For more information, please visit www.athenex.com.CONTACTSSteve Rubis Athenex, Inc. Email: stevenrubis@athenex.comDaniel Lang, MD Athenex, Inc. Email: danlang@athenex.comTim McCarthy LifeSci Advisors, LLC Email: tim@lifesciadvisors.com
GlobeNewswire · 10/22 12:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATNX. Analyze the recent business situations of Athenex through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATNX stock price target is 27.41 with a high estimate of 38.00 and a low estimate of 16.67.
EPS
Institutional Holdings
Institutions: 171
Institutional Holdings: 55.26M
% Owned: 59.20%
Shares Outstanding: 93.34M
TypeInstitutionsShares
Increased
33
4.57M
New
48
5.42M
Decreased
47
2.28M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.74%
Pharmaceuticals & Medical Research
+0.82%
Key Executives
Chairman/Chief Executive Officer/Director
Johnson Lau
Chief Financial Officer
Randoll Sze
Corporate Executive
William Zuo
Chief Operating Officer
Jeffrey Yordon
Senior Director
Daniel Lang
Other
Rudolf Kwan
Other
Simon Pedder
Lead Director/Independent Director
Kim Campbell
Director
Manson Fok
Director
Robert Spiegel
Independent Director
Stephanie Davis
Independent Director
Jordan Kanfer
Independent Director
Tiong Lu Koh
Independent Director
Kwan Hung Tsang
Independent Director
Benson Tsang
Independent Director
John Vierling
Independent Director
Jinn Wu
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ATNX
Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company's Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Athenex Inc stock information, including NASDAQ:ATNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATNX stock methods without spending real money on the virtual paper trading platform.